M&A Deal Summary

Roche Acquires Foundation Medicine

On June 19, 2019, Roche acquired life science company Foundation Medicine for 5.3B USD

Acquisition Highlights
  • This is Roche’s 23rd transaction in the Life Science sector.
  • This is Roche’s 4th largest (disclosed) transaction.
  • This is Roche’s 22nd transaction in the United States.
  • This is Roche’s 4th transaction in Massachusetts.

M&A Deal Summary
Date 2019-06-19
Target Foundation Medicine
Sector Life Science
Buyer(s) Roche
Deal Type Add-on Acquisition
Deal Value 5.3B USD
Advisor(s) Goldman Sachs (Financial)
Goodwin Procter (Legal)

Target

Foundation Medicine

Cambridge, Massachusetts, United States
Foundation Medicine, Inc. is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 60.4B CHF (2023)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 35 of 42
Sector (Life Science) 23 of 29
Type (Add-on Acquisition) 32 of 35
State (Massachusetts) 4 of 5
Country (United States) 22 of 28
Year (2019) 2 of 3
Size (of disclosed) 4 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-02-25 Spark Therapeutics

Philadelphia, Pennsylvania, United States

Spark Therapeutics, Inc. is a gene therapy provider seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark Therapeutics was founded in 2013 and is based in Philadelphia, Pennsylvania.

Buy $4.3B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-15 Promedior

Lexington, Massachusetts, United States

Promedior, Inc. is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with scar tissue, compromising function and ultimately leading to organ failure. Promedior focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis and myelofibrosis. Promedior, Inc. was founded in 2006 and is based in Lexington, Massachusetts.

Buy $1.4B
Mergr

Product

Company

Legal